Sponsor or institution
Clinical trials and research at Verastem, Inc.
As of November 12, 2026, Find a Trial lists 5 clinical trials run by Verastem, Inc. that are recruiting, at sites in 17 countries (most in Australia (5), United States (5), Puerto Rico (2)). By phase: Phase 2 (3), Phase 1/2 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 17Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| VS-7375 with or without antibodies for KRAS G12D colorectal cancer | Phase 2 | Scottsdale, Arizona and 29 other locations | Recruiting | Jun 22, 2026 |
| KRAS G12D-mutant non-small cell lung cancer: test VS-7375 alone and with cetuximab | Phase 2 | Scottsdale, Arizona and 23 other locations | Recruiting | Jun 22, 2026 |
| KRAS G12D-mutated pancreatic cancer: VS-7375 with or without cetuximab | Phase 2 | Los Angeles, California and 37 other locations | Recruiting | Jun 12, 2026 |
| VS-7375 for adults with KRAS G12D-mutated advanced solid tumors. | Phase 1/2 | Los Angeles, California and 21 other locations | Recruiting | Jun 13, 2025 |
| Combination treatment for recurrent low-grade serous ovarian cancer | Phase 3 | Phoenix, Arizona and 104 other locations | Recruiting | Oct 10, 2023 |
All recruiting trials (5)
-
VS-7375 with or without antibodies for KRAS G12D colorectal cancer
This study tests VS-7375 alone and in combination with cetuximab or panitumumab (and cetuximab plus mFOLFOX6) in people with metastatic KRAS G12D colorectal cancer to see if it is safe and effective.
-
KRAS G12D-mutant non-small cell lung cancer: test VS-7375 alone and with cetuximab
This study tests VS-7375, by itself and with cetuximab, in people whose advanced NSCLC has a KRAS G12D mutation.
-
KRAS G12D-mutated pancreatic cancer: VS-7375 with or without cetuximab
This study tests whether VS-7375, alone or with cetuximab, can help people with metastatic PDAC that carries the KRAS G12D mutation.
-
VS-7375 for adults with KRAS G12D-mutated advanced solid tumors.
This trial tests VS-7375, alone and combined with other cancer drugs, in adults with unresectable or metastatic solid tumors that have the KRAS G12D mutation.
-
Combination treatment for recurrent low-grade serous ovarian cancer
This study is testing a new combination of two drugs for people with recurrent low-grade serous ovarian cancer to see if it helps them live longer without their cancer getting worse compared to standard treatments.
Quick answers
How many clinical trials run by Verastem, Inc. are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 17 countries. The most sites are in Australia (5 trials), United States (5 trials), Puerto Rico (2 trials), France (2 trials), Spain (2 trials). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1/2: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.